Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | PPID | Q08752 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11355645 | 0.90 | POLB (0.55) | SYKPOLBALDH1A1MAPTGAA | |
| SCHEMBL8168563 | 0.86 | MAPT (0.53) | SYKPOLBALDH1A1CYP1A2MAPT | |
| SCHEMBL29860111 | 0.86 | MAPT (0.53) | SYKPOLBALDH1A1CYP1A2MAPT | |
| SCHEMBL6904254 | 0.85 | ALDH1A1 (0.51) | SYKEGFRALDH1A1CYP1A2MAPT | |
| Hydrochloric Acid SCHEMBL8170506 | 0.84 | ALDH1A1 (0.50) | SYKEGFRALDH1A1CYP1A2MAPT | |
| SCHEMBL8819532 | 0.83 | POLB (0.52) | SYKPOLBEGFRMAPTNLRP3 | |
| SCHEMBL5287728 | 0.83 | MAPT (0.54) | SYKPOLBEGFRALDH1A1MAPT | |
| SCHEMBL8903194 | 0.83 | POLB (0.49) | SYKPOLBALDH1A1MAPTGAA | |
| SCHEMBL20839664 | 0.83 | SYK (0.49) | SYKPOLBALDH1A1MAPTMAPK1 | |
| SCHEMBL7565590 | 0.83 | ALDH1A1 (0.54) | SYKPOLBEGFRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6824786-B2 | TOPICAL APPLYING COSMETIC | YU RUEY J (US) | 2004-11-30 | — | — | US | claimed |
| EP-1455734-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | Yu, Ruey J., Dr. (US) | 2004-09-15 | — | — | EP | claimed |
| US-20030108496-A1 | Compositions comprising phenyl-glycine derivatives | YU RUEY J (US) | 2003-06-12 | — | — | US | claimed |
| WO-2003045338-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | YU RUEY J (US) | 2003-06-05 | — | — | WO | claimed |
| US-20210353683-A1 | ADDITIVE FOR MEDIUM FOR PROMOTING PRODUCTION OF PARACRINE FACTOR | NISSAN CHEMICAL CORPORATION (JP) | 2021-11-18 | — | — | US | disclosed |
| EP-3851519-A1 | ADDITIVE FOR MEDIUM FOR PROMOTING PRODUCTION OF PARACRINE FACTOR | Nissan Chemical Corporation (JP) | 2021-07-21 | — | — | EP | disclosed |
| CN-112805268-A | Medium supplement reagent for promoting production of paracrine factor | 日产化学株式会社 | 2021-05-14 | — | — | CN | disclosed |
| US-20200165194-A1 | ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME | NISSAN CHEMICAL CORPORATION (JP) | 2020-05-28 | — | — | US | disclosed |
| US-6824786-B2 | TOPICAL APPLYING COSMETIC | YU RUEY J (US) | 2004-11-30 | — | — | US | disclosed |
| EP-1455734-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | Yu, Ruey J., Dr. (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030108496-A1 | Compositions comprising phenyl-glycine derivatives | YU RUEY J (US) | 2003-06-12 | — | — | US | disclosed |
| WO-2003045338-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | YU RUEY J (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108496-A1 | Compositions comprising phenyl-glycine derivatives | GRHPR, ARL1, SUCLG1 | SYK 3044/4885POLB 2304/4885EGFR 530/4885 |
| US-20210353683-A1 | ADDITIVE FOR MEDIUM FOR PROMOTING PRODUCTION OF PARACRINE FACTOR | HGF, HDGF, FGF2 | SYK 3827/4885POLB 3054/4885EGFR 357/4885 |
| US-20200165194-A1 | ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME | NEFM, FGF2, FGF1 | SYK 2776/4885POLB 3336/4885EGFR 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.